Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aldevron
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.
- In Vitro Diagnostics
- Large Molecule
- Synthesis Technologies, Production Processes
Drug Discovery Tools